Axa’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Axa’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-116,785	Closed	-$248K	–	1427
2018 Q3	$248K	Hold	116,785	–	–	﹤0.01%	1266
2018 Q2	$270K	Sell	116,785 -15,000	-11%	-$43.7K	﹤0.01%	1253
2018 Q1	$419K	Hold	131,785	–	–	﹤0.01%	1200
2017 Q4	$540K	Buy	131,785 +30,006	+29%	+$131K	﹤0.01%	1142
2017 Q3	$460K	Buy	101,779 +13,079	+15%	+$53K	﹤0.01%	1119
2017 Q2	$295K	Buy	+88,700	New	+$368K	﹤0.01%	1142

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Axa's OMED Position: Q4 2018 in Review

Axa sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 116,785 shares — an estimated $248K sold.

Axa first reported a position in OMED in Q2 2017 and held it in 6 quarters. The position peaked at $540K in Q4 2017. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

Axa reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Axa sold 116,785 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $248K.
Axa first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 6 quarters.
Axa's OncoMed Pharmaceuticals, Inc. position peaked at $540K in Q4 2017.
42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Axa's 13F filing for Q4 2018, filed 13 Feb 2019.